IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
0.249
+0.008 (3.49%)
At close: Dec 20, 2024, 4:00 PM
0.250
+0.001 (0.48%)
After-hours: Dec 20, 2024, 7:51 PM EST
IN8bio Employees
IN8bio had 31 employees as of December 31, 2023. The number of employees increased by 5 or 19.23% compared to the previous year.
Employees
31
Change (1Y)
5
Growth (1Y)
19.23%
Revenue / Employee
n/a
Profits / Employee
-$1,028,226
Market Cap
18.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Dec 31, 2021 | 19 | 5 | 35.71% |
| Dec 31, 2020 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Flora Growth | 108 |
| Carisma Therapeutics | 107 |
| Senti Biosciences | 48 |
| Aptose Biosciences | 36 |
| MEI Pharma | 28 |
| Bullfrog AI | 11 |
| XTL Biopharmaceuticals | 7 |
| MIRA Pharmaceuticals | 3 |
INAB News
- 11 days ago - IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting - GlobeNewsWire
- 5 weeks ago - IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 3 months ago - IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia - GlobeNewsWire
- 4 months ago - IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100 - GlobeNewsWire
- 6 months ago - IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - GlobeNewsWire
- 6 months ago - IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 - GlobeNewsWire
- 7 months ago - IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting - GlobeNewsWire